BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chidamide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Chidamide\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04985890-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT04985890)
DESCRIPTION:Chidamide\, phase 2.\nStudy: A Proof of Concept Study to Evalua
 te the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservo
 ir\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04985890
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06066905-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase na readout est. (NCT06066905)
DESCRIPTION:Chidamide\, phase na.\nStudy: A Study of Chidamide With AZA in 
 MRD Positive AML After Transplant\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06066905
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220162-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chidamide: Phase 2 readout est. (NCT06220162)
DESCRIPTION:Chidamide\, phase 2.\nStudy: VAC Regimen for AML Patients Who F
 ailed to Response to VA Regimen\nEstimated primary completion: 1 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06220162
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04512534-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chidamide: Phase 2 readout est. (NCT04512534)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: Sinti
 limab Combined With Chidamide in Treating Peripheral T Cell Lymphoma\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04512534
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05958719-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Chidamide: Phase 2 readout est. (NCT05958719)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: Chida
 mide in Combination With Azacitidine\, Liposomal Mitoxantrone\, and Predni
 sone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Ce
 ll Lymphoma\nEstimated primary completion: 30 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05958719
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06451861-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Chidamide: Phase 2 readout est. (NCT06451861)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Randomized Study of ABC-14 Regimen
  Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06451861
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06739395)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Precision Medicine Trial Based on 
 Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
 \nEstimated primary completion: 31 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151106-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06151106)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: Chida
 mide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T
 -cell Lymphoma\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06151106
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06556862-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06556862)
DESCRIPTION:Chidamide\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Canc
 er After Failure of CDK4/6 Inhibitor\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 56862
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304232-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT07304232)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Post-transplantation Maintenance T
 herapy With Cidabenamide in Patients With Intermediate/High-risk AML\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07304232
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570447-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06570447)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Gl
 ofitamab Combination With Chidamide in Patients With Recurrent/Refractory 
 DLBCL\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06570447
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06255795-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 3 readout est. (NCT06255795)
DESCRIPTION:Chidamide\, phase 3.\nStudy: The Efficacy and Safety of Chidami
 de\, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in th
 e Treatment of Newly Diagnosed\, Stage III to IV Extranodal Natural Killer
 /T-Cell Lymphoma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06255795
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745193-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Chidamide: Phase 2 readout est. (NCT06745193)
DESCRIPTION:Chidamide\, phase 2.\nStudy: A Prospective\, Randomized\, Open\
 , Phase II Clinical Study of Chidamide in Combination with Camrelizumab an
 d Apatinib for Advanced Esophageal Cancer\nEstimated primary completion: 1
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chida
 mide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06745193
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07884708-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Chidamide: Phase 2 readout est. (NCT07884708)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Chidamide\, Lenalidomide\, and Rit
 uximab in Newly Diagnosed Elderly/unFit DE-DLBCL\nEstimated primary comple
 tion: 11 March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07884708
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320963-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270328
DTEND;VALUE=DATE:20270329
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07320963)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: Chidamide in Combination With To
 ripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.\
 nEstimated primary completion: 28 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07320963
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616336-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Chidamide: Phase 2 readout est. (NCT07616336)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Chidamide Monotherapy for Intermed
 iate-to-High-Risk Myelodysplastic Syndromes\nEstimated primary completion:
  31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chida
 mide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07616336
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671717-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Chidamide: Phase na readout est. (NCT06671717)
DESCRIPTION:Chidamide\, phase na\, Peripheral T-Cell Lymphoma.\nStudy: Pral
 atrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/R
 elapsed Peripheral T-cell Lymphoma\nEstimated primary completion: April 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06671717
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930118-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Chidamide: Phase 2 readout est. (NCT06930118)
DESCRIPTION:Chidamide\, phase 2\, Colorectal Cancer.\nStudy: The Aim of Thi
 s Study is to Assess the Efficacy and Safety of Chidamide\, Regorafenib in
  Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanc
 ed Colorectal Cancer in Third-line Therapy and Subsequent Lines.\nEstimate
 d primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06930118
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07577986-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07577986)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: A Safety and Efficacy Trial of C
 hidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Vira
 l Reservoir\nEstimated primary completion: 1 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07577986
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951997-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Chidamide: Phase 2 readout est. (NCT06951997)
DESCRIPTION:Chidamide\, phase 2.\nStudy: QL1706 Plus Chidamide\, AG as Firs
 t-line Treatment for Metastatic Pancreatic Cancer\nEstimated primary compl
 etion: 15 May 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 hidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06951997
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489989-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Chidamide: Phase 2 readout est. (NCT07489989)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: En
 hancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and P
 D-1 Inhibitor Combination.\nEstimated primary completion: 15 May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07489989
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421948-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT06421948)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: Lin
 perlisib Combined With Chidamide in Patients With PTCL\nEstimated primary 
 completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06421948
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552324-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Chidamide: Phase 2 readout est. (NCT07552324)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: St
 udy on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisafto
 clax in Combination With Pola-R-CHP\nEstimated primary completion: 31 May 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07552324
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05833724-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Chidamide: Phase 2 readout est. (NCT05833724)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: Chida
 mide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R
 /R PTCL)\nEstimated primary completion: June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05833724
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393361-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Chidamide: Phase 2 readout est. (NCT06393361)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Chidamide Decitabine Plus Anti-PD-
 1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refu
 sed Transplant.\nEstimated primary completion: 1 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06393361
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570849-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Chidamide: Phase 2 readout est. (NCT07570849)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Chidamide Combined With Chemothera
 py and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cho
 langiocarcinoma\nEstimated primary completion: 1 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07570849
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545967-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Chidamide: Phase 1 readout est. (NCT07545967)
DESCRIPTION:Chidamide\, phase 1.\nStudy: Re-radiotherapy Combined With Chid
 amide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma
  After Radiotherapy\nEstimated primary completion: 1 July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07545967
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093710-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07093710)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: Gol
 idocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide 
 in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma\nEst
 imated primary completion: 1 August 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07093710
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532552-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Chidamide: Phase 2 readout est. (NCT06532552)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Comparison of VA (Venetoclax\, Aza
 citidine)\, VACl (VA\, Cladribine)\, VACh (VA\, Chidamide)\, and Alternati
 ng VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia\nEstimated primary 
 completion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06532552
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891157-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Chidamide: Phase 2 readout est. (NCT06891157)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Ch
 idamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Ce
 ll Lymphoma With Other Molecular Subtypes\nEstimated primary completion: 2
 0 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidam
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06891157
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133763-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07133763)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: Application of PD-1 Inhibitors\,
  Tenofovir\, Chidamide\, and Lenalidomide in Relapsed/Refractory EBV-assoc
 iated Lymphoproliferative Disorders.\nEstimated primary completion: 1 Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 33763
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133776-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07133776)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: Application of PD-1 Inhibitors C
 ombined With Tenofovir\, Chidamide and Lenalidomide in the Treatment of EB
 V-associated Diseases.\nEstimated primary completion: 1 September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07133776
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139353-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07139353)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: Lin
 perlisib Combined With Chidamide in the Treatment of Relapsed or Refractor
 y Peripheral T-cell Lymphoma\nEstimated primary completion: 1 September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07139353
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514936-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Chidamide: Phase 3 readout est. (NCT07514936)
DESCRIPTION:Chidamide\, phase 3.\nStudy: Venetoclax-Azacitidine in Combinat
 ion With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukae
 mia\nEstimated primary completion: 30 September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07514936
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678933-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Chidamide: Phase 3 readout est. (NCT05678933)
DESCRIPTION:Chidamide\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: AC-CH
 OP Versus CHOP in Patients With Previously Untreated PTCL-TFH\nEstimated p
 rimary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05678933
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550336-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Chidamide: Phase 2 readout est. (NCT06550336)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: A Cli
 nical Study Assessing the Efficacy of Chidamide for CD30-positive Peripher
 al T-cell Lymphoma (PTCL).\nEstimated primary completion: 30 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06550336
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06386302-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Chidamide: Phase na readout est. (NCT06386302)
DESCRIPTION:Chidamide\, phase na.\nStudy: Chidamide\, Venetoclax\, and Azac
 itidine for Newly Diagnosed Acute Myeloid Leukemia\nEstimated primary comp
 letion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06386302
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270200-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT05270200)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: Single Arm Study of Post-transpl
 ant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia
  Relapse\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05270200
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158386-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06158386)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Chidamide Combined With Linperlisi
 bon for the Treatment of Refractory/Relapsed Follicular Lymphoma\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06158386
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538180-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Chidamide: Phase 2 readout est. (NCT07538180)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Serplulimab\, Chidamide\, and Ritu
 ximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 D
 ouble-Expressor DLBCL\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07538180
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890506-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Chidamide: Phase 2 readout est. (NCT07890506)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Chidamide Combined With Benmelstob
 art\, Nab-paclitaxel\, and SBRT as Second-Line Treatment for Advanced BTC\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07890506
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706959-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07706959)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: New
  Genotype-guided Treatment in Newly Diagnosed PTCL\nEstimated primary comp
 letion: January 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07706959
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339527-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07339527)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: EZH2 Inhibitor Zeprumetostat in 
 Combination Therapy for Patients With Relapsed or Refractory Mature T-cell
  and NK-cell Lymphomas\nEstimated primary completion: 1 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07339527
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518602-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:Chidamide: Phase 2 readout est. (NCT07518602)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Efficacy and Safety of Chidamide+S
 intilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendoc
 rine Carcinoma\nEstimated primary completion: 27 March 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07518602
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412262-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Chidamide: Phase 2 readout est. (NCT07412262)
DESCRIPTION:Chidamide\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non
 -Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy 
 and High Yes-associated Protein (YAP) Expression\nEstimated primary comple
 tion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07412262
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783100-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Chidamide: Phase 2 readout est. (NCT07783100)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Venetoclax\, Chidamide\, and Chigl
 itazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leu
 kemia\nEstimated primary completion: 31 March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07783100
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415980-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07415980)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: Phase Ib/II Study of Polatuzumab
  Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed El
 derly Patients With Double-Expressor DLBCL\nEstimated primary completion: 
 1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidami
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7415980
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058103-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Chidamide: Phase 2 readout est. (NCT07058103)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Tislelizumab \, Cyclophosphamide\,
  Mitoxantrone Liposomes\, Chidamide\, and Prednisone in the Treatment of R
 /R AITL\nEstimated primary completion: 1 April 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07058103
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601607-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07601607)
DESCRIPTION:Chidamide\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse
  Large B-cell Lymphoma\nEstimated primary completion: 30 May 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07601607
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497985-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Chidamide: Phase 3 readout est. (NCT06497985)
DESCRIPTION:Chidamide\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 idinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Color
 ectal Cancer Patients\nEstimated primary completion: 31 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06497985
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643636-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Chidamide: Phase 2 readout est. (NCT07643636)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Chidamide\, Venetoclax\, Azacitidi
 ne\, and Homoharringtonine for High-risk Fit AML\nEstimated primary comple
 tion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ch
 idamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07643636
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927049-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Chidamide: Phase 2/3 readout est. (NCT07927049)
DESCRIPTION:Chidamide\, phase 2/3\, Colorectal Cancer.\nStudy: Evaluating t
 he Efficacy of Chidamide in the Treatment of Initial Unresectable Metastat
 ic Colorectal Cancer With High Expression of SULF1\nEstimated primary comp
 letion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07927049
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927075-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Chidamide: Phase 2/3 readout est. (NCT07927075)
DESCRIPTION:Chidamide\, phase 2/3\, Colorectal Cancer.\nStudy: Evaluating t
 he Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With Hig
 h SULF1 Expression\nEstimated primary completion: 1 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07927075
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397832-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Chidamide: Phase 2 readout est. (NCT07397832)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: CR
 P Regimen in Treating Elderly Patients With Previously Untreated Double-Po
 sitive DLBCL\nEstimated primary completion: 30 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397832
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746245-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Chidamide: Phase 2 readout est. (NCT07746245)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: The E
 fficacy of CAPCT in Patients With PTCL\nEstimated primary completion: 31 J
 uly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07746
 245
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168317-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Chidamide: Phase 2 readout est. (NCT07168317)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Tislelizumab \, Cyclophosphamide\,
  Mitoxantrone Liposomes\, Chidamide\, and Prednisone in the Treatment of N
 ew Diagnosed AITL\nEstimated primary completion: 1 August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07168317
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07074457-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Chidamide: Phase na readout est. (NCT07074457)
DESCRIPTION:Chidamide\, phase na\, Peripheral T-Cell Lymphoma.\nStudy: Chid
 amide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients\nE
 stimated primary completion: 1 August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07074457
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774377-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Chidamide: Phase 3 readout est. (NCT07774377)
DESCRIPTION:Chidamide\, phase 3.\nStudy: Chidamide Maintenance to Prevent R
 elapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T
 -Lymphoblastic Leukemia/Lymphoma\nEstimated primary completion: 15 August 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07774377
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934537-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Chidamide: Phase 4 readout est. (NCT07934537)
DESCRIPTION:Chidamide\, phase 4.\nStudy: Efficacy and Safety of Chidamide C
 ombined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Tr
 eatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)\nEstimated primary 
 completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07934537
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159620-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Chidamide: Phase 2 readout est. (NCT07159620)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Venetoclax Combined With Azacitidi
 ne\, Chidamide\, Vindesine\, and Dexamethasone in Newly Diagnosed ETP-ALL 
 Like Patients\nEstimated primary completion: 1 September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07159620
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06516978-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Chidamide: Phase 2 readout est. (NCT06516978)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and 
 Pola-RCHP in Previously Untreated Patients With DLBCL\nEstimated primary c
 ompletion: 1 October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06516978
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917624-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Chidamide: Phase 2 readout est. (NCT07917624)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Pr
 ophylactic Strategies for Mitigating Central Nervous System Relapse in Dif
 fuse Large B-Cell Lymphoma\nEstimated primary completion: 31 October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07917624
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937124-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Chidamide: Phase 2 readout est. (NCT07937124)
DESCRIPTION:Chidamide\, phase 2.\nStudy: An All-Oral Combination of Ivoside
 nib\, Sonrotoclax\, and Chidamide for Newly Diagnosed Acute Myeloid Leukem
 ia With an IDH1 Mutation (ISC)\nEstimated primary completion: 14 December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07937124
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757387-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT06757387)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: Chi
 damide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphom
 a\nEstimated primary completion: 30 December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06757387
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07635992-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Chidamide: Phase 1 readout est. (NCT07635992)
DESCRIPTION:Chidamide\, phase 1.\nStudy: A Clinical Study Evaluating the Sa
 fety\, Tolerability\, and Effect on HIV Reservoir of Ibalizumab Combined W
 ith Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV\
 nEstimated primary completion: 31 December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07635992
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754890-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07754890)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: Golidocitinib and Chidamide for 
 Cutaneous T-Cell Lymphoma\nEstimated primary completion: 31 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07754890
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318831-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Chidamide: Phase 2 readout est. (NCT07318831)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Phase II Study of Chidamide-Dinutu
 ximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma i
 n Children\nEstimated primary completion: 31 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07318831
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07380984-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Chidamide: Phase 2 readout est. (NCT07380984)
DESCRIPTION:Chidamide\, phase 2.\nStudy: PD-1 Antibody-based Therapy With C
 oncurrent RT for Early-stage NKTCL\nEstimated primary completion: February
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07380984
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542912-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Chidamide: Phase na readout est. (NCT07542912)
DESCRIPTION:Chidamide\, phase na.\nStudy: Sintilimab\, Chidamide\, and Azac
 itidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma\nEstimated 
 primary completion: 1 June 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/chidamide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07542912
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507318-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Chidamide: Phase 2 readout est. (NCT07507318)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Ch
 idamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Compl
 ete Remission\nEstimated primary completion: 30 June 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07507318
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04025450-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290715
DTEND;VALUE=DATE:20290716
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT04025450)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: Comparation of Chidamide Plus VR
 D (Bortezomib\, Lenalidomide\, Dexamethasone) With VRD Regimen for Primary
  High-Risk Multiple Myeloma Patients\nEstimated primary completion: 15 Jul
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0402545
 0
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072221-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Chidamide: Phase na readout est. (NCT07072221)
DESCRIPTION:Chidamide\, phase na\, Peripheral T-Cell Lymphoma.\nStudy: Bend
 amustine Combined With Chidamide and Lenalidomide for Relapsed and Refract
 ory PTCL Patients\nEstimated primary completion: 1 August 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07072221
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493109-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Chidamide: Phase 3 readout est. (NCT07493109)
DESCRIPTION:Chidamide\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: Ch
 idamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patient
 s Initially Treated With R-CHOP\nEstimated primary completion: 30 Septembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749310
 9
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493330-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20291212
DTEND;VALUE=DATE:20291213
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07493330)
DESCRIPTION:Chidamide\, phase 1/2.\nStudy: Genotype-guided Targeted Agents 
 Plus EZH2i for Primary Refractory PTCL\nEstimated primary completion: 12 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidami
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7493330
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493148-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Chidamide: Phase 2 readout est. (NCT07493148)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Ch
 idamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenanc
 e in Elderly Newly Diagnosed MYC/BCL2+ DLBCL\nEstimated primary completion
 : 30 December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 hidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07493148
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890585-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06890585)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Za
 nubrutinib\, Chidamide\, and Rituximab Induction With or Without CHOP Vers
 us R-CHOP in Newly Diagnosed Double-Expressor DLBCL\nEstimated primary com
 pletion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06890585
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598578-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Chidamide: Phase 1 readout est. (NCT07598578)
DESCRIPTION:Chidamide\, phase 1\, Peripheral T-Cell Lymphoma.\nStudy: An Op
 en-label\, Single-arm\, Multicenter Phase II Clinical Study of Azacitidine
 \, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Re
 fractory/Relapsed Peripheral T-cell Lymphoma.\nEstimated primary completio
 n: 1 January 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ch
 idamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07598578
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05088226-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Chidamide: Phase 2 readout est. (NCT05088226)
DESCRIPTION:Chidamide\, phase 2.\nStudy: Ruxolitinib and Chidamide Intensif
 ied Bu/CY Conditioning Regimen\nEstimated primary completion: 1 June 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05088226
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947967-2286@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Chidamide: Phase 3 readout est. (NCT06947967)
DESCRIPTION:Chidamide\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: Tucid
 inostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymp
 homa With Follicular Helper of T Cell Phenotype\nEstimated primary complet
 ion: December 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 hidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06947967
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
